Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 1

2(40.0%)

Phase 3

1(20.0%)

5Total

Phase 2(2)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07068516Phase 3Not Yet Recruiting

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

Role: lead

NCT06766305Phase 1Recruiting

QL1706 Combined With SOX Used in Theperioperative Treatment

Role: lead

NCT06610799Phase 1Recruiting

Study of IBI363 in Patients with Advanced First-line Gastric Cancer

Role: lead

NCT06642857Recruiting

Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.

Role: lead

NCT06614179Recruiting

A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established

Role: lead

NCT05739045Phase 2Recruiting

Nivolumab Combined With SOX Used in the Perioperative Treatment

Role: lead

NCT06374901Phase 2Not Yet Recruiting

Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

Role: lead

All 7 trials loaded